The Oregon ADHD-1000: A new longitudinal data resource enriched for clinical cases and multiple levels of analysis
- PMID: 36848718
- PMCID: PMC9984785
- DOI: 10.1016/j.dcn.2023.101222
The Oregon ADHD-1000: A new longitudinal data resource enriched for clinical cases and multiple levels of analysis
Abstract
The fields of developmental psychopathology, developmental neuroscience, and behavioral genetics are increasingly moving toward a data sharing model to improve reproducibility, robustness, and generalizability of findings. This approach is particularly critical for understanding attention-deficit/hyperactivity disorder (ADHD), which has unique public health importance given its early onset, high prevalence, individual variability, and causal association with co-occurring and later developing problems. A further priority concerns multi-disciplinary/multi-method datasets that can span different units of analysis. Here, we describe a public dataset using a case-control design for ADHD that includes: multi-method, multi-measure, multi-informant, multi-trait data, and multi-clinician evaluation and phenotyping. It spans > 12 years of annual follow-up with a lag longitudinal design allowing age-based analyses spanning age 7-19 + years with a full age range from 7 to 21. Measures span genetic and epigenetic (DNA methylation) array data; EEG, functional and structural MRI neuroimaging; and psychophysiological, psychosocial, clinical and functional outcomes data. The resource also benefits from an autism spectrum disorder add-on cohort and a cross sectional case-control ADHD cohort from a different geographical region for replication and generalizability. Datasets allowing for integration from genes to nervous system to behavior represent the "next generation" of researchable cohorts for ADHD and developmental psychopathology.
Keywords: Attention-deficit/hyperactivity disorder; Case-control longitudinal; Design; Genetic and epigenetic array; Neuroimaging; Public dataset; Pyschophysiological.
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Damien A. Fair reports a relationship with NOUS Imaging Inc that includes: board membership and equity or stocks.
Figures



Similar articles
-
Prevalence and treatment of mental, behavioral, and developmental disorders in children with co-occurring autism spectrum disorder and attention-deficit/hyperactivity disorder: A population-based study.Autism Res. 2023 Apr;16(4):855-867. doi: 10.1002/aur.2894. Epub 2023 Jan 16. Autism Res. 2023. PMID: 36644987 Free PMC article.
-
Association of White Matter Structure With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.JAMA Psychiatry. 2017 Nov 1;74(11):1120-1128. doi: 10.1001/jamapsychiatry.2017.2573. JAMA Psychiatry. 2017. PMID: 28877317 Free PMC article.
-
Cumulative Effects of Resting-State Connectivity Across All Brain Networks Significantly Correlate with Attention-Deficit Hyperactivity Disorder Symptoms.J Neurosci. 2024 Mar 6;44(10):e1202232023. doi: 10.1523/JNEUROSCI.1202-23.2023. J Neurosci. 2024. PMID: 38286629 Free PMC article.
-
Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.J Child Psychol Psychiatry. 2021 Jun;62(6):680-700. doi: 10.1111/jcpp.13305. Epub 2020 Aug 26. J Child Psychol Psychiatry. 2021. PMID: 32845025
-
A critical review of developmental exposure to particulate matter, autism spectrum disorder, and attention deficit hyperactivity disorder.J Environ Sci Health A Tox Hazard Subst Environ Eng. 2018 Jan 28;53(2):174-204. doi: 10.1080/10934529.2017.1383121. Epub 2017 Nov 20. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2018. PMID: 29157090 Review.
Cited by
-
Joint polygenic and environmental risks for childhood attention-deficit/hyperactivity disorder (ADHD) and ADHD symptom dimensions.JCPP Adv. 2023 Mar 16;3(2):e12152. doi: 10.1002/jcv2.12152. eCollection 2023 Jun. JCPP Adv. 2023. PMID: 37753156 Free PMC article.
-
Brain morphology normative modelling platform for abnormality and centile estimation: Brain MoNoCle.Imaging Neurosci (Camb). 2025 Jan 10;3:imag_a_00438. doi: 10.1162/imag_a_00438. eCollection 2025. Imaging Neurosci (Camb). 2025. PMID: 40800979 Free PMC article.
-
Epigenetic age across development in children and adolescents with ADHD.Psychiatry Res. 2025 Mar;345:116373. doi: 10.1016/j.psychres.2025.116373. Epub 2025 Jan 20. Psychiatry Res. 2025. PMID: 39855016
-
Subcortico-Cortical Dysconnectivity in ADHD: A Voxel-Wise Mega-Analysis Across Multiple Cohorts.Am J Psychiatry. 2024 Jun 1;181(6):553-562. doi: 10.1176/appi.ajp.20230026. Epub 2024 Mar 13. Am J Psychiatry. 2024. PMID: 38476041 Free PMC article.
-
The Relationship Between Emotion Dysregulation and Error Monitoring in Adolescents with ADHD.Res Child Adolesc Psychopathol. 2024 Apr;52(4):605-620. doi: 10.1007/s10802-023-01127-z. Epub 2023 Oct 16. Res Child Adolesc Psychopathol. 2024. PMID: 37843650 Free PMC article.
References
-
- Antshel K.M., Russo N. Autism spectrum disorders and ADHD: overlapping phenomenology, diagnostic issues, and treatment considerations. Curr. Psychiatry Rep. 2019;21:34. - PubMed
-
- Asherson P., Agnew-Blais J. Annual research review: does late-onset attention-deficit/hyperactivity disorder exist? J. Child Psychol. Psychiatry. 2019;60:333–352. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical